Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.59 |
| ▸ | MYLK4 | Q86YV6 | 5/20 | 0.57 |
| ▸ | AKT2 | P31751 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662575 | 0.86 | ROCK2 (0.76) | ROCK2ROCK1MYLK4AKT2 | |
| SCHEMBL1254733 | 0.85 | ROCK2 (0.74) | ROCK2ROCK1MYLK4 | |
| Acetic Acid SCHEMBL4661546 | 0.84 | ROCK2 (0.73) | ROCK2ROCK1MYLK4 | |
| SCHEMBL20661019 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20661144 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL21979523 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20661120 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL13457481 | 0.79 | ROCK2 (0.64) | ROCK2 | |
| SCHEMBL1978203 | 0.79 | ROCK2 (0.69) | ROCK2AKT2 | |
| SCHEMBL1254574 | 0.78 | ROCK2 (0.68) | ROCK2ROCK1MYLK4AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015070170-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885MYLK4 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.